Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Good volume today... I'm jumping up and down with excrement.. oops, should that be "excitement"?

Go Deltex! Go Deltex! Go Deltex!

Not sure about Execs and others taking shares in lieu of cash - does this spell the need to conserve cash or was it a preliminary to buying TECO (no posting here, so I know nowt) - they have some Government approval recently so maybe this is the "boost" that others were hoping for.
The sp needs to rise a bit more (say beyond 25p) before these Execs can be sure their gamble has paid off.
Paying execs in shares whenever a sp falls 30% (let's say), is a good idea as it should concentrate their minds---
1) not to over egg the reality
2) to provide rising shareholder value

Re todays, news.

This is great news, now lets hope the NHS budget managers see the CardioQ for what it is. With the publicity that will follow questions should be asked if the CardioQ is not taken up. It has been proved that it saves lives ( the shorter time spent in hospital the longer you live ) and also it saves money. What more are they waiting for.
Due to the NHS lack of ability to make even the simplest decisions, don't expect any huge uptake. But it will come, slowly maybe, but it now ( imho ) looks inevitable. I am still looking to overseas for the real profits to be made.

anyone know when results are?

2005 interims 29th Sept ( so next 6 months may be March ) Finals 2005 were 29th June so probably same month. No notice re interims as yet.

It appears that with Evo jumping ahead of Scap and Kbc on the bid, the shares look in demand ( Kbc now upped there bid to join Evo on the bid ).
With fairly low volume this is starting to look as if there is a decent buyer in the wings. Hard to keep up the top 3 are now vying each other for your shares. All 3 have ticked up the bid within 2 minutes.j

Evo now dropped to bottom of the pile re Bid. I wonder if they have filled an order

Not sure but as a guide, last yrs were released 15th March

On L 2 it is starting to look a bit like yesterday, 5 of the 6 mm's have increased their ask/bid prices, with the other one holding steady. Also 4 have upped the sp within 4 minutes, another possible sign to an increase, ( again same as yesterday.)

Looking good! Someone likes DEMG. Offer 26.5, bid 24.75
Has someone got wind of some news?
The full-year results in mid March should be interesting.

Arf,

Yes, another nice tick up today. Can't find any reason, as you say results will be interesting. Also soon be another financial year. The NHS management, and the government can't be as bad in the comming financial year, can they, ( o'k probably yes they can ). They must see that every spent early on re CardioQ will save many pounds ( and lives ) later.

Greekman - post 187 very true, however lets not forget the NHS need to spend on eliminating MRSA first. Something CardioQ doesn't protect against.

I held these shares for some time before selling due to lack of confidence in the board to actully land sales. I do hope that one day they will come and like many I believe in CardioQ... Although Delex has many probally hundreds of medical reports backing CardioQ publicity focus continues to be in the wrong areas. Deltex and investors should target the press and media with CardioQ to build pressure on both the NHS and government to fund this ever needed technology.. The more people that know about CardioQ the better chance Deltex has of selling its product before its patient expires and cheap copies are launched into the market!

Just in.

Yet another example of cost savings that can be made.
Cost savings, taking into account the cost of the
Deltex Medical probe and the reduction in whole blood, blood products and
ancillary equipment used, but excluding savings from length of stay reduction,
were approximately 3,500 per patient.
'There are approximately 80,000 patients every year in Europe alone who could
benefit enormously from this approach if it were adopted as a standard of care,
and there is the additional potential for substantial cost savings at
hospitals.'
That's 280 million euro's. When will the powers that be wake up to this fantastic product.

When they stop investing in endless layers of middle management.

sd

Results out, showing a steady but sure progress.
Looking forward the future does look very promising. As has been mentioned many times with the CardioQ, once this really does gather momentum, there will be no stopping it. All IMHO of course.

yep.. steady as she goes.....still one for the long term.. I'll continue to hold and will look to top up when SP falls below 18p. imho SP is bound to drift down during quiet periods..

Very true skyhigh, hope your also keeping an eye on Deltex's patients.... Expirey etc... Its also worth doing some research on other companies that have medical technology to offer and am having difficulty like Deltex selling their product.... Having said this you could always take matters into your own hands and run a special sponsored "whatever" to raise money to buy your local hospital a CardioQ!!....... Just a thought.

Re the RNS

Looking good. It appears the dam has finally started to break. Don't mind a share placing at all as the proceeds are for all the right reasons. It's a light placing percentage wise anyway.
All indications for the next 6 to 12 months look to increasing, sales of the monitors and probes.

I like the increase in U.K. monitor sales announced at the AGM a few days ago. It was something like 34 monitors in the U.K. in the whole of 2005. Now they say they've already had 24 U.K. sales in 2006, so if that covers 4 months, that suggests 72 monitors will be sold for the whole of 2006. That's more than double last year! Even being pessimistic, they have almost made 70% of last year's U.K. monitor sales in the first 4 months of this year, so they should comfortably exceed last year's sales.

I miagine that NICE approval has had something to do with this.

Just released.
A glimmer of hope in what is a very bad week over all...

LONDON (AFX) - Deltex Medical Group PLC said an audit conducted at the Royal Alexandria Hospital in Paisley found that patients subject to haemodynamic optimisation using its CardioQ device had a mean length of stay in hospital of 9.55 days compared to 12 days for those patients that had received a standardised anaesthetic.

Dr David Alcorn, who has been in charge of auditing the procedure at the hospital, said: 'We are greatly encouraged by the results achieved. This has major benefits not only for patients but for clinicians and hospitals throughout the country.'

Deltex Medical's Chief Executive, Andy Hill, said: 'The evidence from this audit comprises further validation of the clinical and cost effectiveness of the CardioQ.'